Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmala Biotech Holdings's quarterly market cap
declined
from Nov. 2025 (C$10.86 Mil) to Feb. 2026 (C$10.35 Mil) but then
increased
from Feb. 2026 (C$10.35 Mil) to May. 2026 (C$18.57 Mil).
Pharmala Biotech Holdings's annual market cap
declined
from Aug. 2023 (C$18.94 Mil) to Aug. 2024 (C$8.15 Mil) but then
increased
from Aug. 2024 (C$8.15 Mil) to Aug. 2025 (C$14.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pharmala Biotech Holdings's Enterprise Value for Today is C$27.61 Mil.
Pharmala Biotech Holdings (XCNQ:MDMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pharmala Biotech Holdings Market Cap Related Terms
Pharmala Biotech Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:MDMA vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Pharmala Biotech Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmala Biotech Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Pharmala Biotech Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmala Biotech Holdings (XCNQ:MDMA) has a Market Cap of C$27.86 Mil as of Aug. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pharmala Biotech Holdings and its competitors. According to the industry distribution chart, Pharmala Biotech Holdings ranks #1088 out of 1421 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Pharmala Biotech Holdings' Market Cap too high?
Pharmala Biotech Holdings' current Market Cap is C$27.86 Mil. Based on the distribution chart, Pharmala Biotech Holdings ranks #1088 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmala Biotech Holdings has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmala Biotech Holdings ranks #1088 out of 1421 companies for Market Cap. This places Pharmala Biotech Holdings in the lower half of its industry. The industry median Market Cap is 123.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 123.85, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pharmala Biotech Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 123.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmala Biotech Holdings's current Market Cap is C$27.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (XCNQ:MDMA) is currently considered Fairly Valued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.25 — trading right at its estimated fair value. The current Market Cap is C$27.86 Mil. Pharmala Biotech Holdings' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Pharmala Biotech Holdings (XCNQ:MDMA), the current Market Cap is C$27.86 Mil as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmala Biotech Holdings (XCNQ:MDMA) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued.
The current stock price of C$0.25 is trading 0% below its estimated GF Value™ of C$0.25.
GuruFocus considers Pharmala Biotech Holdings to be Fairly Valued.
Key valuation signals for XCNQ:MDMA:
Market Cap: C$27.86 Mil
GF Value™: C$0.25 vs. price of C$0.25 (0% below fair value)
No single metric tells the full story. See the XCNQ:MDMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
38GF Score
Get the complete analysis for XCNQ:MDMA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:MDMA has been successfully added to your 
